Polpharma Biologics Group Announces That Its Joint Venture Bioeq Has Submitted a Biologics License Application (BLA) for Biosimilar Ranibizumab to the U.S. Food and Drug Administration (FDA)
Polpharma Biologics Group announces that its joint venture company with Santo Holding (Strüngmann Group), Bioeq, has submitted a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for their biosimilar candidate of the ophthalmological drug Ranibizumab (Lucentis®).
The reference product is a monoclonal anti-angiogenic antibody fragment (Fab) used to treat various types of macular-degenerative diseases such as neovascular (wet) age-related macular degeneration, diabetic retinopathy, macular edemas and myopic choroidal neovascularization. Worldwide, at least 25 to 30 million people are affected by age-related macular degeneration. The launch of a biosimilar Ranibizumab can increase market competition, reduce cost and expand patient access with proven analytical and clinical similarity to the original product. It works by inhibiting vascular endothelial growth factor (VEGF), which is responsible for the excessive formation of blood vessels in the retina.
Subject to FDA's approval of this BLA, the product will be exclusively commercialized by Coherus BioSciences, Inc. in the United States.
Said submission represents the most recent milestone for Bioeq's ranibizumab biosimilar program and compliments marketing authorization applications submitted to EMA and UK MHRA already in July this year.
Dr Joerg Windisch, CEO of the Polpharma Biologics Group, commented:
“The submission of a BLA to the FDA is a major milestone for any therapeutic and brings hope to patients across the US. This announcement carries a tangible promise of treatment choice and improved access to those who suffer from debilitating vision loss, including age-related macular degeneration. This is another representation of our commitment to providing safe and effective medicines to patients.”
1) Lucentis ® is a registered trademark of Genentech Inc.
About Ranibizumab biosimilar
The Ranibizumab biosimilar, previously designated as FYB201 (and also known as CHS-201), has been originally licensed from Formycon AG (FRA: FYB/ WKN A1EWVY), a leading German biosimilars company, and subsequently developed by Bioeq AG, a joint venture between Polpharma Biologics and Santo Holding AG (Strüngmann Group). Phase III clinical trials for FYB201 have clinically demonstrated that the efficacy of FYB201 in patients with nAMD is comparable to that of Lucentis®.
About biosimilars
Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Biosimilars exhibit proven analytical and clinical similarity to their respective branded reference products.
About Polpharma Biologics Group
The Polpharma Biologics Group creates quality biosimilars with a passion to improve lives of patients. The group has built an extensive and growing pipeline of biosimilars to treat a number of medical conditions across major therapeutic areas. Several of these biosimilar assets have already been commercially partnered with the world’s largest biopharmaceutical companies.
The group operates a network of state-of-the-art development and manufacturing facilities across Europe, actively investing in technology, people and know-how, employing over 800 specialists from around the globe.
Learn more at www.polpharmabiologics.com
About Bioeq
Bioeq is a Swiss biopharmaceutical joint venture between the Polpharma Biologics Group and the Strüngmann Group. Bioeq develops, licenses and commercializes biosimilars.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210806005187/en/
Contact information
Joseph Reeds
Head of Marketing, Polpharma Biologics
Joseph.reeds@polpharmabiologics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brands Poised for Growth: NIQ Identifies the Strategies Behind 2025’s Top Performing Innovations9.12.2025 13:00:00 EET | Press release
NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today released its 4th Annual Innovation Vitality Report, revealing the strategies that are helping brands achieve multi-year growth from their innovation pipelines. Drawing on data from over 70,000 manufacturers across 130 categories, the report highlights the practices that double a company’s likelihood of expanding overall sales through top performing innovation. As retailers accelerate shelf refresh cycles and private label competition intensifies, brands are under increasing pressure to design innovations with staying power. NIQ’s findings show that top performing innovators consistently follow a repeatable formula, rooted in strong consumer-led ideas, early performance signals, and cross functional alignment, to build products that deliver long-term, incremental growth across global markets. Key Findings from the 2025 Innovation Vitality Report Winning Innovation Starts Before Launch Brands that invest in true innov
Klarna Now Available on Apple Pay to Customers in France and Italy9.12.2025 12:49:00 EET | Press release
Klarna, the global digital bank and flexible payments provider, has made its flexible payment products available when checking out on Apple Pay in France and Italy. Millions of eligible shoppers can now choose Klarna at checkout online and in-app using their iPhone and iPad, or in-store using their iPhone, and this innovative capability delivers even more convenience, control, and transparency to even more customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209410835/en/ The continued expansion follows strong consumer adoption and momentum in Denmark, Spain, Sweden, the U.S., UK and Canada, where Klarna’s flexible payment options have become a popular way to pay with Apple Pay. With today’s launch, consumers across eight major markets can now choose to shop with Klarna through Apple Pay’s simple and secure experience, and consumers have more choice and flexibility in how they can pay. “We’ve seen incredible exciteme
DNP Achieves 10nm Line Pattern Resolution on Nanoimprint Template for Cutting-Edge Semiconductors9.12.2025 12:12:00 EET | Press release
Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced the development of a nanoimprint lithography (NIL) template featuring a circuit line width of 10 nanometers (nm: 10-9 meter). The new template enables patterning for logic semiconductors equivalent to the 1.4nm generation and meets the miniaturization needs of cutting-edge logic semiconductors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208175160/en/ Template for nanoimprint Background and Aims In line with the shift to more sophisticated devices seen in recent years, demands have emerged for even greater miniaturization in cutting-edge semiconductors, leading to advances in Extreme Ultra-Violet (EUV) lithography-based production. EUV lithography, however, requires substantial capital investment, energy consumption, and operating costs in building production lines and the exposure process. Since 2003, DNP has been developing NIL templates and has successf
Reply Achieves the AWS Agentic AI Specialization and Is Named an Implementation Partner for Amazon Bedrock AgentCore9.12.2025 11:47:00 EET | Press release
Reply [EXM, STAR: REY] announced that it has achieved the Amazon Web Services (AWS) Agentic AI Specialization, a new category within the AWS AI Competency. This recognition positions Reply and its companies specialized in AWS technologies - Data Reply and Storm Reply - among the AWS Partners able to help customers deploy smart, self-operating AI systems that can think, plan, and act autonomously to execute complex business processes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209601808/en/ Through Amazon Bedrock AgentCore, organizations can simplify and secure the development of intelligent agents at scale, interact with enterprise systems, analyze data in real time, and automate complex processes. The specialization further strengthens Reply’s long-standing expertise in AWS technologies and its ability to deliver production-ready autonomous AI systems based on Amazon Bedrock Agents and AWS-native frameworks, enabling
LabelVie Advances AI-Driven Grocery Retail Transformation Through Long-Standing Collaboration with SymphonyAI9.12.2025 11:00:00 EET | Press release
For more than two decades, LabelVie Group has relied on SymphonyAI, a global leader in Vertical AI product platforms, to power its grocery retail transformation. Now, that partnership is entering a new phase — one defined by connected intelligence, predictive precision, and measurable impact across LabelVie’s 270-plus stores in Morocco and Ivory Coast. As one of North Africa’s largest and fastest-growing grocery retail and wholesale operators, LabelVie is advancing its digital modernization through SymphonyAI’s end-to-end retail solutions, which support greater visibility, accuracy, and operational coordination across its growing network. The continued collaboration reinforces a long-term commitment to improving supply-chain processes and store operations as LabelVie expands into new markets and grocery retail formats. “SymphonyAI has been a trusted technology partner for more than two decades,” said Naoual Benamar, General Manager, LabelVie. “Their deep retail expertise and proven AI
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom